News & Perspective
Drugs & Diseases
CME & Education
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Today on Medscape
Business of Medicine
Medical Lifestyle
Science & Technology
Medical Students
Nurses
Pharmacists
Residents
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Friday, January 10, 2025
      News & Perspective Drugs & Diseases CME & Education Video Decision Point
      Perspective > Medscape > MDAngle

      SABCS 2024: Insights on New Data in HR+/HER2- Breast Cancer

      Avan J. Armaghani, MD

      Disclosures

      December 20, 2024

      Dr Armaghani highlights several key advancements in hormone receptor‒positive, HER2-negative breast cancer presented at the 2024 San Antonio Breast Cancer Symposium. The EMBER-3 trial showcased promising data for the oral SERD imlunestrant, demonstrating improved progression-free survival in combination with abemaciclib, particularly in patients with ESR1 mutations.

      The 10-year update from the OlympiA trial reaffirmed the benefits of adjuvant PARP inhibitors in BRCA1/2 mutation carriers, showing long-term survival advantages. Additionally, the SOLTI VALENTINE study on the HER3-directed antibody-drug conjugate HER3-DXd revealed a robust immune response and fewer severe side effects compared with chemotherapy, offering a potential alternative for neoadjuvant therapy in high-risk early breast cancer.

      Comments

      3090D553-9492-4563-8681-AD288FA52ACE
      Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

      processing....

      Feedback
      Help us make reference on Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this article more useful to clinicians.
      Pleasedo not use this form to submit personal or patient medical information or to report adverse drug events. You are encouraged to report adverse drug event information to the FDA.
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Manage Preferences Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      Editions
      English Deutsch Español Français Português
      All material on this website is protected by copyright, Copyright © 1994-2025 by WebMD LLC. This website also contains material copyrighted by 3rd parties.